查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836842

精準醫療市場（按產品類型、應用和最終用戶分類）－2025-2032 年全球預測

Precision Medicine Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

精準醫療市場預計到 2032 年將成長至 3,413.8 億美元，複合年成長率為 11.73%。

主要市場統計數據
基準年2024年 1405.4億美元
預計2025年 1559億美元
預測年份：2032年 3413.8億美元
複合年成長率（%） 11.73%

權威介紹，解釋技術進步、臨床工作流程和生態系統夥伴關係如何推動精準醫療進入主流醫療保健服務

對於尋求根據患者獨特生物學特徵制定治療方案的醫療機構、生物製藥創新者、診斷研發人員和醫療系統而言，精準醫療已從一個夢想概念演變為切實可行的必需品。基因測序、分子診斷和數據分析領域的最新進展，正在將重心從群體層面的干涉轉向有針對性的治療方案，從而提高診斷準確性、最佳化治療方法選擇並縮短試驗的治療週期。如今，這些技術推動因素與不斷變化的臨床工作流程、支付方對價值證據的期望以及成熟的服務供應商生態系統相輔相成，從而加快了臨床醫生和研究人員獲得洞察的時間。

隨著相關人員從概念驗證轉向實用化，診斷、軟體和治療之間的相互作用正在創造新的經營模式和夥伴關係。伴隨測試、基因面板和液態切片等診斷為藥物開發和患者分層提供資訊，而軟體和數據分析則將原始分子數據轉化為可臨床操作的報告。從細胞和基因療法到標靶治療和基於 RNA 的方法的治療創新越來越需要整合的診斷途徑和專門的製造生態系統。因此，有關產品開發、商業化和供應鏈設計的策略選擇取決於對技術依賴性、監管趨勢和最終用戶回應能力的細緻理解。本執行摘要為這些動態提供了一個框架，以幫助領導者確定投資優先順序、降低營運風險並加速具有臨床意義的採用。

深入分析融合診斷技術、不斷變化的監管預期以及分散製造，這些正在從根本上重塑精準醫療策略

精準醫療領域正在經歷幾場變革時期，這些變革正在重塑技術創新、監管和商業化之間的相互關係。分子診斷、就地檢驗和液態切片平台與雲原生分析的互通性日益增強，從而能夠在即時檢驗時提供即時決策支援。這種融合促進了上游發現與下游臨床應用之間的更緊密整合，形成了一個回饋迴路，從而加速了生物標記檢驗和治療最佳化。其次，資料基礎設施和分析技術日趨成熟，使得多中心協作研究能夠透過聯邦學習、隱私保護計算和可擴展的生物資訊學流程進行，而無需犧牲資料管治。因此，現在可以更有效地協調臨床和現實世界資料集，以用於檢驗試驗和上市後證據產生。

第三，法律規範和報銷模式正轉向臨床效用和成本效益的證據，這要求診斷開發者和治療申辦者之間更緊密的合作。這些監管變革正在鼓勵協作開發策略和新的報銷模式，以獎勵已證實的患者獲益。第四，隨著旨在支持細胞和基因療法產能的合約開發與受託製造廠商(CDMO) 的出現，先進療法的生產和供應鏈架構正朝著分散化、模組化和區域化的方向發展。這些轉變降低了物流風險，並支持患者更快獲得治療，但也引入了新的品管和法規遵循要求。最後，付款人的期望和醫療系統採購慣例越來越傾向於能夠在整個護理過程中展現出更佳療效的整合解決方案，這迫使公司設計將診斷、分析和治療途徑整合成一個連貫的價值提案的產品。總而言之，這些轉變迫使公司重新思考跨職能協作，投資於強大的數據策略，並追求靈活的生產和分銷模式，以保持競爭力。

全面評估 2025 年關稅變化和貿易政策動態將如何為精準醫療企業帶來供應鏈風險、採購獎勵和策略在地化壓力。

2025年影響國際貿易和關稅的政策行動將對整個精準醫療價值鏈產生累積效應，影響投入、製造成本和分銷動態。試劑、定序耗材和高精度設備等關鍵零件的關稅上調，可能會增加診斷實驗室和製造商的採購成本。因此，投入成本的上升將擠壓伴隨診斷開發商和支持細胞和基因治療供應鏈的契約製造製造商的利潤率。這些壓力將促使企業重新評估籌資策略，追求供應商多元化，並加速對維持成本和進度可預測至關重要的製造流程的在地化。

除了直接的成本影響外，關稅環境還帶來了時間和物流的不確定性，使資本規劃和產能部署更加複雜。準備進行臨床試驗或擴大商業營運規模的公司可能會面臨進口設備和材料的前置作業時間波動，這可能會延遲新檢測平台的實施以及輸液和生產設施的安裝。因此，公司可能會增加關鍵任務物資的緩衝庫存，或協商包含關稅減免條款的長期供應商合約。此外，關稅政策的變化可能會導致競爭力下降。擁有成熟區域製造地和垂直整合供應鏈的公司可能享有相對優勢，而依賴跨國採購的公司則可能面臨更大的營運摩擦。

關稅也將影響戰略夥伴關係和外國直接投資決策。企業可能會加快近岸外包進程，或尋求與當地製造商或診斷實驗室建立合資企業，以規避貿易壁壘並保持市場進入。這種商業性和營運佈局的再形成通常需要重新協商智慧財產權安排、技術轉移計劃和品質保證通訊協定，以確保跨司法管轄區的合規性。先前共用樣本和設備的跨國聯盟可能會採用其他共同研究模式，減少跨國貨物流動，轉而利用分散式資料分析和本地樣本處理來維持研究的連續性。這些動態相結合，需要積極主動的供應鏈風險評估、情境規劃和合約彈性，以維持專案進度並保護商業性前景。

細分主導的可操作洞察，將產品類型、臨床應用和使用者工作流程結合起來，優先考慮精準醫療領域的投資和打入市場策略

要了解需求促進因素，需要仔細細分產品類型、臨床應用和最終用戶，以確定哪些投資和重點營運能夠產生最大的策略回報。診斷學進一步分為伴隨診斷、基因檢測、液態切片、分子診斷和就地檢驗；而治療學則分為細胞和基因療法、免疫療法、蛋白質替代療法、基於RNA的療法和標靶小分子。伴隨診斷嚴格遵循治療開發時間表，並需要共同檢驗；基因檢測服務依賴於強大的變異解讀流程和合規框架；液態切片平台強調靈敏度和縱向監測；即時檢測則優先考慮簡便性和快速的臨床應用。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 實施人工智慧和機器學習演算法，用於多組體學物標誌物發現和患者分層
  • 擴展次世代定序面板，用於罕見疾病診斷和個人化治療決策
  • 數位雙胞胎技術的出現，用於臨床試驗中的虛擬患者建模和精準治療模擬
  • 將真實世界證據和健康經濟成果整合到精準腫瘤藥物開發策略中
  • 利用 CRISPR 和基因編輯平台進行體內單一基因疾病的校正並加速治療流程
  • 針對查核點抑制劑和細胞療法的新型免疫療法的伴隨診斷檢測的開發
  • 使用穿戴式生物感測器和遠端醫療對分層患者群體進行分散臨床試驗
  • 製藥公司與數位健康Start-Ups建立策略夥伴關係，共同開發個人化護理途徑

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章精準醫療市場（依產品類型）

  • 診斷
    • 伴隨診斷
    • 基因檢測
    • 液態生物檢體
    • 分子診斷
    • 就地檢驗
  • 軟體和數據分析
  • 治療藥物
    • 細胞療法
    • 基因治療
    • 免疫療法
    • 蛋白質替代療法
    • 基於RNA的治療方法
    • 標靶治療

第9章精準醫療市場的應用

  • 自體免疫疾病
  • 心臟病學
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 罕見疾病和遺傳疾病
  • 呼吸系統疾病

第 10 章精準醫療市場（依最終使用者）

  • 生物製藥和生物技術公司
  • 診斷實驗室
  • 醫院和診所
  • 研究機構

第11章 精準醫療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 精準醫療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 精準醫療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • Aranscia, LLC
    • AstraZeneca PLC
    • biocrates life sciences ag
    • bioMerieux SA
    • Bristol-Myers Squibb Company
    • Caris Life Sciences
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • Guardant Health, Inc.
    • healthOme, Inc.
    • Hitachi High-Tech Corporation
    • Illumina, Inc.
    • Johnson & Johnson
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Merck KGaA
    • N-Power Medicine, Inc.
    • Natera Inc.
    • NeoGenomics, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Precision Medicine Group, LLC
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Strata Oncology, Inc.
    • Tempus AI, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Thermo Fisher Scientific Inc.
    • ZS Associates, Inc.
Product Code: MRR-030EE48515D0

The Precision Medicine Market is projected to grow by USD 341.38 billion at a CAGR of 11.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 140.54 billion
Estimated Year [2025] USD 155.90 billion
Forecast Year [2032] USD 341.38 billion
CAGR (%) 11.73%

An authoritative introduction explaining why technological advances, clinical workflows and ecosystem partnerships are driving precision medicine into mainstream healthcare delivery

Precision medicine has evolved from an aspirational concept into a practical imperative for healthcare organizations, biopharmaceutical innovators, diagnostics developers and health systems that seek to align therapies with patient-specific biology. Recent advances in genomic sequencing, molecular diagnostics, and data analytics have shifted the balance from population-level interventions toward targeted approaches that improve diagnostic accuracy, optimize therapeutic selection and reduce trial-and-error treatment cycles. These technological enablers are now complemented by changing clinical workflows, payer expectations for value evidence, and a maturing ecosystem of service providers that reduce time-to-insight for clinicians and researchers alike.

As stakeholders move beyond proof-of-concept to operationalization, the interplay of diagnostics, software and therapeutics generates new business models and partnerships. Diagnostics modalities such as companion tests, genetic panels and liquid biopsies inform drug development and patient stratification, while software and data analytics transform raw molecular data into clinically actionable reports. Therapeutic innovations spanning cell and gene therapies to targeted and RNA-based approaches increasingly require integrated diagnostic pathways and specialized manufacturing ecosystems. Consequently, strategic choices about product development, commercialization, and supply chain design now hinge on a nuanced understanding of technical dependencies, regulatory trajectories and end-user readiness. This executive summary frames those dynamics to help leaders prioritize investments, mitigate operational risk and accelerate clinically meaningful adoption.

Detailed analysis of converging diagnostic technologies, evolving regulatory expectations and decentralizing manufacturing that are fundamentally reshaping precision medicine strategies

The landscape of precision medicine is undergoing several transformative shifts that collectively reconfigure how innovation, regulation and commercialization interconnect. First, diagnostic modalities have diversified and converged: molecular diagnostics, point-of-care testing and liquid biopsy platforms are increasingly interoperable with cloud-native analytics, enabling real-time decision support at the point of care. This convergence fosters tighter integration between upstream discovery and downstream clinical use, creating feedback loops that accelerate biomarker validation and therapeutic optimization. Second, data infrastructure and analytics have matured, with federated learning, privacy-preserving computation and scalable bioinformatics pipelines enabling multi-institutional collaboration without sacrificing data governance. As a result, clinical and real-world datasets can be harmonized more effectively for validation studies and post-market evidence generation.

Third, regulatory frameworks and reimbursement paradigms are shifting toward evidence of clinical utility and cost-effectiveness, requiring closer alignment between diagnostic developers and therapeutic sponsors. This regulatory evolution incentivizes co-development strategies and novel reimbursement models that reward demonstrated patient benefit. Fourth, manufacturing and supply-chain architectures for advanced therapies are decentralizing, with modular, regionalized facilities and contract development and manufacturing organizations (CDMOs) designed to support cell and gene therapy throughput. These shifts reduce logistical risk and support faster patient access but introduce new quality management and regulatory compliance requirements. Finally, payer expectations and health-system procurement practices increasingly favor integrated solutions that demonstrate improved outcomes across the care continuum, prompting companies to design offerings that combine diagnostics, analytics, and therapeutic pathways into coherent value propositions. Taken together, these shifts compel organizations to rethink cross-functional collaboration, invest in robust data strategies, and pursue flexible manufacturing and commercial models to remain competitive.

Comprehensive assessment of how 2025 tariff shifts and trade policy dynamics create supply chain risk, sourcing incentives and strategic localization pressures across precision medicine operations

Policy actions affecting international trade and tariffs in 2025 carry cumulative effects that extend across the precision medicine value chain, influencing inputs, manufacturing costs, and distribution dynamics. Increased duties on key components-such as reagents, sequencing consumables and high-precision instruments-tend to raise procurement costs for diagnostic laboratories and manufacturers. In turn, higher input costs can compress margins for developers of companion diagnostics and for contract manufacturers that support cell and gene therapy supply chains. These pressures incentivize organizations to reassess sourcing strategies, pursue supplier diversification, and accelerate localization of critical manufacturing steps to maintain cost and schedule predictability.

Beyond direct cost impacts, tariff environments introduce timing and logistical uncertainty that complicate capital planning and capacity deployment. Firms preparing clinical trials or scaling commercial operations face greater lead-time variability for imported equipment and materials, which can delay onboarding of new testing platforms or establishment of infusion and manufacturing suites. Consequently, companies are more likely to increase buffer inventories for mission-critical supplies or to negotiate long-term supplier agreements that include tariff mitigation clauses. Moreover, tariff policy shifts can provoke competitive displacement: firms with established regional manufacturing footprints or vertically integrated supply chains may gain relative advantage, while those dependent on cross-border sourcing confront higher operational friction.

Tariffs also influence strategic partnerships and foreign direct investment decisions. Organizations may accelerate nearshoring initiatives or pursue joint ventures with local manufacturers and diagnostic laboratories to circumvent trade barriers and preserve market access. This reshaping of commercial and operational footprints often requires renegotiation of intellectual property arrangements, tech transfer plans and quality assurance protocols to ensure compliance across jurisdictions. Finally, the cumulative impact of tariff policy extends to research collaborations: cross-border consortiums that previously shared samples and instrumentation may adopt alternative collaboration models that reduce cross-border movement of goods, instead leveraging distributed data analysis and local sample processing to maintain research continuity. Taken together, these dynamics require proactive supply-chain risk assessments, scenario planning and contractual flexibility to sustain program timelines and protect commercial prospects.

Actionable segmentation-led insights aligning product types, clinical applications and user workflows to prioritize investments and go-to-market strategies across precision medicine

Understanding demand drivers requires careful segmentation across product type, clinical application and end-user to identify where investment and operational focus generate the greatest strategic returns. Based on product type, the precision medicine ecosystem encompasses Diagnostics, Software & Data Analytics, and Therapeutics; Diagnostics further break down into companion diagnostics, genetic testing, liquid biopsy, molecular diagnostics, and point-of-care testing, while Therapeutics cover cell and gene therapies, immunotherapies, protein replacement, RNA-based modalities and targeted small molecules. Each product category follows a distinct development lifecycle and commercial pathway: companion diagnostics tightly follow therapeutic development timelines and require co-validation, genetic testing services depend on robust variant interpretation pipelines and compliance frameworks, liquid biopsy platforms emphasize sensitivity and longitudinal monitoring, and point-of-care testing prioritizes simplicity and rapid turnaround for clinical adoption.

Based on application, clinical demand centers on oncology, neurology, cardiology, infectious diseases, respiratory conditions, autoimmune disorders, and rare and genetic disorders, with oncology currently representing a major area for biomarker-driven approaches due to established links between genomic alterations and targeted therapeutic response. However, neurology and rare genetic disorders are gaining momentum as improved sequencing and biomarker discovery enable earlier and more precise interventions. Based on end user, adoption pathways vary between biopharmaceutical and biotechnology companies, diagnostic laboratories, hospitals and clinics, and academic and commercial research institutes, each with different procurement cycles, validation requirements and adoption incentives. Biopharmaceutical organizations often seek integrated companion diagnostic solutions to support clinical trials, diagnostic laboratories focus on throughput and reimbursement dynamics, hospitals and clinics require end-to-end workflow integration and clinical utility evidence, and research institutes prioritize flexibility and novel assay development. Recognizing these distinctions enables tailored go-to-market strategies, targeted evidence generation plans and partnership models that match product capabilities to specific clinical and operational needs.

Nuanced regional insights explaining how Americas, Europe-Middle East-Africa and Asia-Pacific dynamics affect regulatory strategy, adoption pathways and commercialization priorities

Regional dynamics shape how technologies are adopted, regulated and commercialized, making geographic strategy a central component of precision medicine planning. In the Americas, the United States ecosystem is characterized by an established venture and innovation infrastructure, a complex but maturing regulatory and reimbursement landscape, and dense clinical trial networks that support rapid technology validation and adoption. Canada and Latin American markets present distinct payer models and variable laboratory capacity, creating opportunities for partnerships that focus on assay validation, training and localized service delivery. In Europe, Middle East & Africa, regulatory harmonization across the European Union and regional initiatives to strengthen genomic literacy are facilitating cross-border clinical studies and multi-center evidence generation, while the Middle East and select African markets are investing in specialized centers of excellence to support rare disease diagnosis and advanced therapeutics; these investments often require bespoke regulatory navigation and capacity-building programs.

In Asia-Pacific, diverse market maturity ranges from highly developed healthcare and manufacturing ecosystems in countries with advanced biotech clusters to rapidly growing demand in emerging markets that prioritize access to affordable diagnostics and telehealth-enabled services. Regional supply-chain specialization in manufacturing and reagent production is notable, and strategic alliances with local partners can accelerate market access and regulatory approvals. Across all regions, interoperability of data systems, adherence to evolving privacy frameworks and alignment with local clinical practice patterns remain pivotal factors for successful deployment. Consequently, organizations should adopt regionally informed strategies that balance centralized R&D with decentralized validation and commercialization efforts, enabling both global standards compliance and local applicability.

Insightful competitive analysis highlighting how vertical integration, platform innovation and strategic partnerships are defining winners across diagnostics, analytics and therapeutics

Competitive dynamics in precision medicine reflect an increasingly collaborative and specialized landscape where established players, niche innovators and platform providers each play distinct roles. Diagnostic manufacturers that focus on companion tests and high-throughput sequencing instruments continue to invest in reducing turnaround time and enhancing analytical sensitivity, while software and data analytics providers are advancing interpretive algorithms, clinical decision support and integration with electronic health records to deliver actionable reports. Therapeutic developers across cell, gene, immunotherapy and RNA modalities are concentrating on robustness of manufacturing, logistics for personalized therapies and building evidence of clinical benefit through close collaboration with diagnostics developers.

Strategic moves across the ecosystem include vertical integration to secure critical supply inputs, targeted acquisitions to fill capability gaps in analytics or manufacturing, and co-development agreements that align diagnostic validation with therapeutic clinical programs. At the same time, a vibrant cohort of startups is pushing innovation in areas such as non-invasive monitoring, decentralized testing platforms and privacy-preserving analytics, creating potential partnership and acquisition targets for larger organizations. Contract manufacturing and service providers that specialize in advanced therapy manufacturing and supply-chain orchestration are gaining prominence as therapeutic pipelines transition from clinical trials to routine use. Investors and corporate development teams increasingly prioritize assets that demonstrate real-world clinical utility, regulatory readiness and scalable operational models, shifting competition toward ecosystems that combine technical capability with integrated evidence generation and commercial readiness.

Practical, high-impact recommendations for leaders to synchronize diagnostics and therapeutics, harden supply chains and build data-driven commercial strategies

Industry leaders must act with deliberate strategies that address technological complexity, regulatory evolution and operational fragility. First, align diagnostic development with therapeutic pipelines through formal co-development agreements and synchronized validation plans to ensure clinical utility evidence is generated in tandem with therapeutic trials. This approach reduces commercialization friction and enhances payer engagement by demonstrating linked clinical outcomes. Second, invest in resilient supply chains through multi-sourcing of critical reagents, regional manufacturing partnerships and contingency inventory strategies to mitigate tariff exposure and logistical disruptions. Third, prioritize data governance and interoperability by implementing standardized data models, adopting privacy-preserving computation methods and investing in clinician-facing decision support that integrates seamlessly with existing electronic health records.

Fourth, adopt flexible manufacturing strategies for advanced therapies that combine centralized expertise with regional capacity, enabling both quality consistency and faster patient access. Fifth, build commercial models that articulate clear value propositions for payers and health systems, emphasizing improved clinical pathways and measurable outcomes rather than standalone technology features. Sixth, pursue targeted partnerships with local diagnostic laboratories, research institutes and health systems to accelerate validation and adoption across diverse clinical settings. Finally, implement continuous scenario planning and regulatory intelligence functions to anticipate policy shifts, tariff changes and reimbursement trends, enabling rapid adjustments to operational plans and investment priorities. Collectively, these actions support scalable deployment, protect program timelines, and increase the probability of sustained clinical and commercial success.

Transparent research methodology combining primary stakeholder interviews, evidence mapping and scenario analysis to ensure reproducible, actionable insights for precision medicine leaders

The research underpinning this analysis integrates primary interviews, secondary literature synthesis and structured evidence mapping to ensure robust, actionable conclusions. Primary inputs include qualitative interviews with clinical leaders, diagnostics developers, therapeutic sponsors, manufacturing specialists and policy experts to capture operational realities and strategic priorities across the value chain. Secondary inputs encompass peer-reviewed literature, regulatory guidance documents, technical white papers and open-source clinical guidelines to contextualize technological trajectories and compliance requirements. Evidence mapping was employed to trace linkages between diagnostics capabilities, analytic workflows and therapeutic co-dependencies, allowing identification of choke points and opportunities for intervention.

Analytical methods combine comparative case analysis of recent co-development programs, supply-chain scenario modeling to assess exposure to trade policy shifts, and stakeholder-aligned value-mapping to prioritize investments by clinical impact and operational feasibility. Throughout the research process, attention was given to data provenance, reproducibility of analytic assumptions and alignment with prevailing regulatory frameworks. Limitations and areas for further in-depth study were identified, including the need for longitudinal post-deployment evidence on clinical utility, deeper cost-to-serve analyses for decentralized manufacturing models, and expanded stakeholder interviews in emerging geographies to refine regional implementation pathways.

A decisive conclusion emphasizing coordinated action across diagnostics, data and therapeutics to convert technical promise into sustained clinical and commercial impact

In conclusion, precision medicine now occupies a strategic intersection of technology, clinical practice and commercial strategy where coordinated action delivers outsized impact. The maturation of diagnostics, advances in software and analytics, and the proliferation of sophisticated therapeutics together create opportunities to improve patient outcomes and optimize care pathways. However, these opportunities come with operational complexity: supply-chain fragility, evolving regulatory expectations, and the need for demonstrable clinical utility require disciplined cross-functional collaboration and adaptive planning.

Organizations that succeed will be those that align diagnostic validation with therapeutic development, invest in resilient and regionally aware supply chains, deploy robust data governance and interoperability frameworks, and craft commercial models that articulate measurable value to payers and health systems. By adopting the strategic actions outlined here and engaging in targeted, regionally informed execution, leaders can translate technical promise into sustained clinical and commercial progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of artificial intelligence and machine learning algorithms for multiomic biomarker discovery and patient stratification
  • 5.2. Expansion of next-generation sequencing panels for rare disease diagnostics and personalized therapeutic decision making
  • 5.3. Emergence of digital twin technologies for virtual patient modeling and precision treatment simulation in clinical trials
  • 5.4. Integration of real-world evidence and health economic outcomes into precision oncology drug development strategies
  • 5.5. Adoption of CRISPR and gene editing platforms for in vivo correction of monogenic disorders and therapeutic pipeline acceleration
  • 5.6. Development of companion diagnostic assays for novel immunotherapies targeting checkpoint inhibitors and cell therapies
  • 5.7. Implementation of decentralized clinical trials leveraging wearable biosensors and telehealth for stratified patient cohorts
  • 5.8. Strategic partnerships between pharmaceutical companies and digital health startups to co-develop personalized care pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Precision Medicine Market, by Product Type

  • 8.1. Diagnostics
    • 8.1.1. Companion Diagnostics
    • 8.1.2. Genetic Testing
    • 8.1.3. Liquid Biopsy
    • 8.1.4. Molecular Diagnostics
    • 8.1.5. Point-of-Care Testing
  • 8.2. Software & Data Analytics
  • 8.3. Therapeutics
    • 8.3.1. Cell Therapy
    • 8.3.2. Gene Therapy
    • 8.3.3. Immunotherapy
    • 8.3.4. Protein Replacement Therapy
    • 8.3.5. RNA-Based Therapy
    • 8.3.6. Targeted Therapy

9. Precision Medicine Market, by Application

  • 9.1. Autoimmune Diseases
  • 9.2. Cardiology
  • 9.3. Infectious Diseases
  • 9.4. Neurology
  • 9.5. Oncology
  • 9.6. Rare & Genetic Disorders
  • 9.7. Respiratory Diseases

10. Precision Medicine Market, by End User

  • 10.1. Biopharmaceutical & Biotechnology Companies
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Clinics
  • 10.4. Research Institutes

11. Precision Medicine Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Precision Medicine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Precision Medicine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AbbVie Inc.
    • 14.3.2. Amgen Inc.
    • 14.3.3. Aranscia, LLC
    • 14.3.4. AstraZeneca PLC
    • 14.3.5. biocrates life sciences ag
    • 14.3.6. bioMerieux S.A.
    • 14.3.7. Bristol-Myers Squibb Company
    • 14.3.8. Caris Life Sciences
    • 14.3.9. Exact Sciences Corporation
    • 14.3.10. F. Hoffmann-La Roche AG
    • 14.3.11. Gilead Sciences, Inc.
    • 14.3.12. Guardant Health, Inc.
    • 14.3.13. healthOme, Inc.
    • 14.3.14. Hitachi High-Tech Corporation
    • 14.3.15. Illumina, Inc.
    • 14.3.16. Johnson & Johnson
    • 14.3.17. Laboratory Corporation of America Holdings
    • 14.3.18. Medtronic PLC
    • 14.3.19. Merck KGaA
    • 14.3.20. N-Power Medicine, Inc.
    • 14.3.21. Natera Inc.
    • 14.3.22. NeoGenomics, Inc.
    • 14.3.23. Novartis AG
    • 14.3.24. Pfizer, Inc.
    • 14.3.25. Precision Medicine Group, LLC
    • 14.3.26. QIAGEN N.V.
    • 14.3.27. Quest Diagnostics Incorporated
    • 14.3.28. Sanofi SA
    • 14.3.29. Strata Oncology, Inc.
    • 14.3.30. Tempus AI, Inc.
    • 14.3.31. Teva Pharmaceutical Industries Ltd.
    • 14.3.32. Thermo Fisher Scientific Inc.
    • 14.3.33. ZS Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRECISION MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRECISION MEDICINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRECISION MEDICINE MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRECISION MEDICINE MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRECISION MEDICINE MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRECISION MEDICINE MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRECISION MEDICINE MARKET SIZE, BY SOFTWARE & DATA ANALYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRECISION MEDICINE MARKET SIZE, BY PROTEIN REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RNA-BASED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRECISION MEDICINE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRECISION MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRECISION MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRECISION MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRECISION MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RARE & GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PRECISION MEDICINE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PRECISION MEDICINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PRECISION MEDICINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. GCC PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. GCC PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. GCC PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. BRICS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRICS PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRICS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. BRICS PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. BRICS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 308. BRICS PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 309. BRICS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. BRICS PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. BRICS PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. BRICS PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. G7 PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. G7 PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. G7 PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. G7 PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 318. G7 PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 319. G7 PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 320. G7 PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 321. G7 PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. G7 PRECISION MEDICINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. G7 PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. G7 PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. NATO PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. NATO PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. NATO PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. NATO PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 330. NATO PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 331. NATO PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 332. NATO PRECISION MEDICINE MARKET SIZE, BY THERAPEUTICS, 2025-20